Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

By sjmartinez • April 27, 2025

Jaiswal V, Hanif M, Mashkoor Y, Prasad T, Fonarow GC. Reply: Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy. JACC Adv. 2025 Apr 14;4(5):101696. doi: 10.1016/j.jacadv.2025.101696. Epub ahead of print. PMID: 40286362.

Tags: Cardiology/Epi, Publications

Clinical outcomes among individuals with systemic inflammation following myocardial infarction: Insights from the veterans affairs healthcare system

Sandhu AT, Furst A, Rodriguez F, Kalwani N, Maron DJ, Nallamshetty S, Din N, Fan M, Khachatourian K, Skaar JR, Tonnu-Mihara I. Clinical outcomes among[...]

Age and sex specific coronary plaque characteristics among South Asians: Insights from the DILWALE CTA study

Satish P, Vajramani A, Gupta S, Ma TW, Prasad T, Lakshmanan S, Budoff M, Kalra DK, Khan MS, Leipsic J, Alsaid A, Kulkarni A. Age[...]

Comparing incidence of heart failure in individuals with enlarged cardiac chambers versus diabetes

Mirjalili SR, Atlas K, Reeves AP, Zhang C, Wasserthal J, Azimi A, Hashemi A, Mozafarybazargany M, Ghaffari Jolfayi A, Atlas T, Henschke CI, Yankelevitz DF,[...]